Global Immune Globulin Intravenous Market Size By Type (IVIg Liquid, IVIg Powder), By Application (Immunodeficiency, Autoimmune Disease), By Region, And Segment Forecasts, 2023 to 2032

The Global Immune Globulin Intravenous (IVIG) Market was valued at USD 13.4 billion in 2023 and is projected to reach USD 24.6 billion by 2031, expanding at a CAGR of 8.1% during the forecast period from 2023 to 2031. This growth is driven by the increasing prevalence of immunodeficiency diseases, rising geriatric population, and expanding therapeutic applications of IVIG in neurological, hematological, and autoimmune disorders. Additionally, improved diagnostic rates and greater awareness among healthcare professionals regarding IVIG therapies are fostering market growth globally.

Drivers:

1. Rising Incidence of Primary Immunodeficiency Diseases (PID):

IVIG is the primary treatment for patients with PID. The growing awareness and enhanced diagnostic capabilities have led to a surge in diagnosed cases, especially in developed countries, thereby increasing the demand for immune globulin therapy.

2. Expanding Therapeutic Use in Autoimmune and Neurological Disorders:

Apart from immunodeficiency treatment, IVIG is now used for conditions like chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome, and myasthenia gravis. This diversification is fueling market expansion.

3. Growing Aging Population:

The elderly are more susceptible to immune disorders and neurological diseases, making them a key demographic for IVIG therapy, thereby contributing significantly to the market's upward trajectory.

Restraints:

1. High Cost of Therapy:

IVIG treatment is expensive due to the complex production process and the need for large plasma volumes. This cost barrier restricts access, particularly in low- and middle-income countries.

2. Supply Chain and Plasma Collection Limitations:

The market is highly dependent on plasma donation and complex fractionation procedures. Limited supply of plasma poses a significant restraint to market scalability and stability.

Opportunity:

1. Technological Innovations in Plasma Fractionation:

Advancements in fractionation and purification processes are improving yield and quality, offering cost-effective and efficient production, thus paving the way for new entrants and product innovations.

2. Untapped Potential in Emerging Markets:

Regions such as Asia-Pacific and Latin America are witnessing a surge in healthcare infrastructure development and increased diagnosis rates, offering lucrative opportunities for IVIG manufacturers and distributors.

Market by System Type Insights:

The Lyophilized IVIG segment led the market in 2023, favored for its longer shelf life and ease of storage, making it a preferred choice in both hospital and home-care settings. However, the Liquid IVIG segment is expected to witness the fastest growth owing to its convenience in administration and increasing adoption in outpatient infusion centers.

Market by End-use Insights:

Hospitals accounted for the largest market share in 2023, driven by high patient footfall, robust reimbursement systems, and the availability of specialized healthcare professionals. Home Care is emerging as a fast-growing segment, encouraged by rising patient preference for comfort, lower treatment costs, and advances in self-administration techniques.

Market by Regional Insights:

North America dominated the global IVIG market in 2023, owing to the high prevalence of immunodeficiency disorders, well-established plasma collection infrastructure, and favorable reimbursement policies. Asia-Pacific is anticipated to register the highest growth rate, driven by improved healthcare access, expanding medical tourism, and increased awareness campaigns in countries like India, China, and South Korea.

Competitive Scenario:

Key players in the global IVIG market include Grifols S.A., CSL Behring, Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A., Bio Products Laboratory Ltd, China Biologic Products Holdings, Inc., and Baxter International Inc. These companies are engaging in strategic collaborations, expanding plasma collection centers, and investing in R&D to enhance their product portfolios.

Scope of Work – Global Immune Globulin Intravenous Market

Key Market Developments:

2023: Grifols S.A. announced the opening of 10 new plasma donation centers across the U.S. to strengthen its supply chain resilience.

2024: Takeda Pharmaceutical launched a next-generation IVIG product with improved infusion speed and safety profile.

2025: CSL Behring partnered with leading hospitals in India and Brazil to expand patient access to IVIG therapy.

FAQs:

What is the current market size of the Global Immune Globulin Intravenous Market?

The market was valued at USD 13.4 billion in 2023.

What is the major growth driver of the Global Immune Globulin Intravenous Market?

The rising incidence of primary immunodeficiency diseases and expanded therapeutic applications are the primary growth drivers.

Which is the largest region during the forecast period in the Global Immune Globulin Intravenous Market?

North America holds the largest market share due to robust healthcare infrastructure and diagnostic capabilities.

Which segment accounted for the largest market share in Global Immune Globulin Intravenous Market?

The hospital segment accounted for the largest share in 2023.

Who are the key market players in the Global Immune Globulin Intravenous Market?

Major players include Grifols S.A., CSL Behring, Takeda Pharmaceutical, Octapharma, and Kedrion S.p.A.